Study of Serum Levels of Visfatin Amongst Pre-Diabetic Obese Patients | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 48, Volume 86, Issue 1, January 2022, Page 306-311 PDF (670.36 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2022.212014 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Salem Ali Alnoggah  ; Abdelmonem Fathy Zeid; Hatem M. Salem; Ahmad Baraka
| ||||
| Abstract | ||||
| Background: Insulin resistance, pre-diabetes, and obesity have all been linked to excess adiposity. Proinflammatory adipokine visfatin is thought to play a key role in type 2 diabetes inflammation. Objective: This study aimed to estimate visfatin level among prediabetic obese patients and to observe and detect the interplay between visfatin, insulin resistance and obesity. Patients and methods: 96 adult subjects were studied in case-control research at Internal Medicine Department and Clinical Pathology Department, Zagazig University Hospital. The study was carried out from January 2021 to November 2021. Subjects were divided into 3 groups: Group (1) included 24 healthy individuals as a control group, group (2) included 48 prediabetic individuals and group (3) that included 24 patients type 2 diabetes who never been treated in any of these. Serum visfatin was assessed in all participants. Results: Diabetes mellitus (DM) patients had higher visfatin levels than those with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). Visfatin had a significant positive correlation with BMI, WC, FBS, PPS, HA1c, LDL, fasting insulin, and HOMA IR, while HDL had a significant negative correlation. Conclusion: Visfatin levels were significantly linked to type 2 diabetes. HOMA-IR, fasting insulin, and BMI all showed a strong positive correlation with visfatin levels, suggesting that it may be a useful biomarker for detecting type 2 diabetes. | ||||
| Keywords | ||||
| Visfatin; Prediabetes | ||||
|
Statistics Article View: 228 PDF Download: 239 |
||||
